Breast Cancer

Jasmeet C. Singh, MD, discusses results from a retrospective analysis looking at the effectiveness of dose dense doxorubicin and cyclophosphamide followed by paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive breast cancer.

Patrick Neven, MD, outlines the design of the phase III MONALEESA-3 trial in hormone receptor–positive, HER2-negative advanced breast cancer.

Rita Nanda, MD, discusses ongoing advances with immunotherapy in triple-negative breast cancer, as well as develops in the HER2-negative breast cancer paradigm.

Melissa K. Accordino, MD, MS, discusses the utility of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer.

Eileen Connolly, MD, PhD, reflects on novel radiation techniques, as well as ongoing research and challenges with radiation therapy in breast cancer.

Howard A. "Skip" Burris, III, MD, FASCO, FACP, chief medical officer and president, Clinical Operations, Sarah Cannon Research Institute, 2019-2020 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses investigational immunotherapy approaches in triple-negative breast cancer (TNBC).

Melissa K. Accordino, MD, MS, discusses the treatment options for patients with hormone receptor-positive, HER2-negative breast cancer.

Dawn L. Hershman, MD, MS, discusses current treatment considerations in premenopausal women with early-stage, hormone receptor-positive breast cancer.

Dawn Hershman, MD, MS, professor of medicine and epidemiology, leader of the Breast Cancer Program of the Herbert Irving Comprehensive Cancer Center at Columbia University, discusses the use of endocrine therapy in premenopausal women with early-stage hormone receptor (HR)–positive, HER2-negative breast cancer.

Kevin Kalinsky, MD, MS, highlights recent developments in triple-negative breast cancer, including the potential role of immunotherapy in the neoadjuvant setting.

Although most breast tumors are not immunogenic, evidence indicates that triple-negative breast cancer expressing PD-L1 is a strong candidate for immunotherapy, explained Leisha A. Emens, MD, PhD, in a presentation on recent trials of immunotherapy alone and in combination with anti–PD-1 therapy.

Naoto Ueno, MD, PhD, FACP, discusses residual cancer burden and immunotherapy in inflammatory breast cancer.

OncLive interviewed experts at the State of the Science Summits™ in January 2020 on what they are going to work on improving in clinical practice this year.

Kevin Kalinsky, MD, MS, discusses the clinical impact of the combination of atezolizumab and nab-paclitaxel in triple-negative breast cancer.

He James Zhu, MD, PhD, discusses potential strategies to mitigate the toxicities of elective nodal irradiation in breast cancer.

Peter Schmid, MD, PhD, discusses the benefit of pembrolizumab when added to neoadjuvant chemotherapy in patients with triple-negative breast cancer.

Therapeutic developments in cancer were rewarded with a wave of approvals in 2019.

Howard A. "Skip" Burris, III, MD, FASCO, FACP, chief medical officer and president, Clinical Operations, Sarah Cannon Research Institute, 2019 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses ongoing research with antibody-drug conjugates (ADCs) in triple-negative breast cancer.

The 37th Annual Miami Breast Cancer Conference provides practical guidance on cutting-edge developments in the treatment of breast cancer.

Kurt W. Tauer, MD, FACP, discusses the expansion of subtyping in breast cancer.

He James Zhu, MD, PhD, discusses the role of elective nodal irradiation in breast cancer and research efforts that may answer some remaining questions with this modality.

Howard A. "Skip" Burris, III, MD, FACP, FASCO, discusses the progress that has been made in metastatic triple-negative breast cancer and the work being done to broaden the utility of novel approaches.

Denise Yardley, MD, discusses the utility of CDK4/6 inhibitors in hormone receptor

Stephanie L. Graff, MD, discusses the importance of using genomic risk to tailor treatment to patients with early-stage hormone receptor-positive, HER2-negative disease, the benefit of extended endocrine therapy, and ongoing research with CDK4/6 inhibitors and immunotherapy.

Stephanie L. Graff, MD, discusses the utility of extended adjuvant therapy in women with early-stage hormone receptor-positive, HER2-negative breast cancer.